UNLABELLED: Pulmonary function tests were obtained in 11 patients with primary ciliary dyskinesia. Their mean age was 15 years (range 6-32). Their pulmonary function was obstructive, with a vital capacity (mean+/-SD) of 75%+/-20% predicted, a forced expiratory volume in 1s (FEV1) of 63%+/-20% predicted and a raised residual volume of 169%+/-50% predicted. After inhalation of 200 microg of salbutamol the mean change in FEV1 was + 13.2%+/-9.6% of the baseline value. In the 10 oldest patients, lung function had been measured at regular intervals during 3 20 years. Interestingly, during childhood and adolescence the evolution was not unfavourable: vital capacity increased by 8%+/-20% and FEV1 remained stable (mean change 0.3%+/-12%). Only 2 patients had an unfavourable evolution. CONCLUSION: At time of diagnosis, patients with primary ciliary dyskinesia have partially reversible obstructive airway disease. During regular follow up and therapy, there is no evidence of a further decline in lung function. Patients with associated immunodeficiency or important damage at the start of therapy may have a worse prognosis.
UNLABELLED: Pulmonary function tests were obtained in 11 patients with primary ciliary dyskinesia. Their mean age was 15 years (range 6-32). Their pulmonary function was obstructive, with a vital capacity (mean+/-SD) of 75%+/-20% predicted, a forced expiratory volume in 1s (FEV1) of 63%+/-20% predicted and a raised residual volume of 169%+/-50% predicted. After inhalation of 200 microg of salbutamol the mean change in FEV1 was + 13.2%+/-9.6% of the baseline value. In the 10 oldest patients, lung function had been measured at regular intervals during 3 20 years. Interestingly, during childhood and adolescence the evolution was not unfavourable: vital capacity increased by 8%+/-20% and FEV1 remained stable (mean change 0.3%+/-12%). Only 2 patients had an unfavourable evolution. CONCLUSION: At time of diagnosis, patients with primary ciliary dyskinesia have partially reversible obstructive airway disease. During regular follow up and therapy, there is no evidence of a further decline in lung function. Patients with associated immunodeficiency or important damage at the start of therapy may have a worse prognosis.
Authors: BreAnna Kinghorn; Sharon McNamara; Alan Genatossio; Erin Sullivan; Molly Siegel; Irma Bauer; Charles Clem; Robin C Johnson; Miriam Davis; Anne Griffiths; William Wheeler; Katherine Johnson; Stephanie D Davis; Margaret W Leigh; Margaret Rosenfeld; Jessica Pittman Journal: Ann Am Thorac Soc Date: 2020-09
Authors: Rohit S Loomba; Michael Danduran; Kim G Nielsen; Astrid M Ring; Joshua Kovach; Robert H Anderson Journal: Pediatr Cardiol Date: 2016-11-23 Impact factor: 1.655
Authors: Margaret W Leigh; Amjad Horani; BreAnna Kinghorn; Michael G O'Connor; Maimoona A Zariwala; Michael R Knowles Journal: Transl Sci Rare Dis Date: 2019-07-04
Authors: Michael R Knowles; Leigh Anne Daniels; Stephanie D Davis; Maimoona A Zariwala; Margaret W Leigh Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405